| The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. | gastric, |
| c-MET oncogene protein was frequently overexpressed in Iranian gastric carcinomas | gastric, |
| C-Met proto-oncogene enhances the migration and invasion of tongue cancer cells through the expressions of matrix metalloproteinase-1, -2, and -9, and promotes tongue cancer cell growth | tongue, |
| Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. | tongue, |
| The MET oncogene is a functional marker of a glioblastoma stem cell subtype. | glioblastoma, |
| Expression of the c-Met proto-oncogene and Integrin alpha5beta1 in human gastric cardia adenocarcinoma. | gastric, |
| Overexpression of c-Met in cervical intraepithelial neoplasia. | cervical, |
| c-Met oncogene overexpression is an important parameter in cervical early oncogenesis and may have a role in malignant transformation of cervical epithelial cells. | cervical, |
| Our findings point to a tumor suppressor role for ETS2 in human NSCLC pathogenesis through inhibition of the MET proto-oncogene. | lung, |
| The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. | glioblastoma, |
| Amplication of the MET protooncogene has been associated with resistance to gefitinib or erlotinib in about 5% of patients, initially responsive to the drug. Somatic mutations in the TK domain of MET have been described in non-small cell lung cancer | lung, |
| The impact of genomic changes on treatment of lung cancer. | lung, |
| reciprocal activating crosstalk between c-Met and CAV1 promoted oncogenic signaling of c-Met contributed to the initiation and progression of HCC. | liver, |
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | kidney, |
| Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. | ovarian, |
| Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms. | ovarian, |
| MET gene in the oncogenesis of maxillary carcinosarcoma and is indicative of the common clonal origin of both malignant components. | sarcoma, |
| Results strongly suggest that the MET receptor influences the oncogenic properties of cervical carcinoma cells in vitro and in vivo. | cervical, |
| Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions. | glioma, |
| Pro-oncogenic Roles of HLXB9 Protein in Insulinoma Cells through Interaction with Nono Protein and Down-regulation of the c-Met Inhibitor Cblb (Casitas B-lineage Lymphoma b). | lymphoma, |